AngioDynamics (NASDAQ:ANGO Shareholders Incur Further Losses as Stock Declines 20% This Week, Taking Three-year Losses to 76%
AngioDynamics (NASDAQ:ANGO Shareholders Incur Further Losses as Stock Declines 20% This Week, Taking Three-year Losses to 76%
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of AngioDynamics, Inc. (NASDAQ:ANGO), who have seen the share price tank a massive 76% over a three year period. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it mildly. On top of that, the share price is down 20% in the last week. Importantly, this could be a market reaction to the recently released financial results. You can check out the latest numbers in our company report.
正如每位投資者所知,不是每次波動都能命中甜蜜點。但如果您偶爾遭受大額虧損,那就是個問題。所以,請花點時間同情 angiodynamics 公司的長期股東們。這些股東在過去三年中看到股價暴跌了整整76%。這可能會讓人嚴重懷疑最初購買該股票的決定的合理性,委婉地說。除此之外,股價在上週下跌了20%。重要的是,這可能是對最近發佈的財務結果的市場反應。您可以在我們的公司報告中查看最新數據。
Since AngioDynamics has shed US$63m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
由於 angiodynamics 在過去7天內市值減少了美元6300萬,讓我們看看更長期的下降是否是由企業經濟驅動的。
Because AngioDynamics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
由於 angiodynamics 在過去十二個月中虧損,我們認爲市場目前可能更關注營業收入和營業收入增長。當一個公司沒有盈利時,我們通常希望看到良好的營業收入增長。正如你可以想象的,快速的營業收入增長,如果能持續,通常會導致快速的利潤增長。
In the last three years, AngioDynamics saw its revenue grow by 0.9% per year, compound. That's not a very high growth rate considering it doesn't make profits. Nonetheless, it's fair to say the rapidly declining share price (down 21%, compound, over three years) suggests the market is very disappointed with this level of growth. We generally don't try to 'catch the falling knife'. Before considering a purchase, take a look at the losses the company is racking up.
在過去的三年裏,angiodynamics 的營業收入年均複合增長率爲0.9%。考慮到該公司沒有盈利,這並不是一個很高的增長率。儘管如此,可以說股價的快速下降(三年內累計下跌21%)表明市場對這種增長水平非常失望。我們通常不會試圖「接住掉下的刀」。在考慮購買之前,請看一下該公司正在積累的虧損。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下圖顯示了收益和營收隨時間變化的情況(如果你點擊圖像,可以看到更多細節):
This free interactive report on AngioDynamics' balance sheet strength is a great place to start, if you want to investigate the stock further.
這份關於angiodynamics資產負債表實力的免費互動報告是進一步調查股票的絕佳起點。
A Different Perspective
不同的觀點
Investors in AngioDynamics had a tough year, with a total loss of 14%, against a market gain of about 34%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. However, the loss over the last year isn't as bad as the 10% per annum loss investors have suffered over the last half decade. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for AngioDynamics you should be aware of.
AngioDynamics的投資者度過了艱難的一年,總損失達到14%,而市場收益約爲34%。 然而,請記住,即使是最好的股票有時也會在十二個月的時間內表現不佳。 然而,過去一年的損失並不像投資者在過去半個世紀中每年損失10%那麼糟糕。 在我們能夠投入大量熱情之前,我們需要看到關鍵指標的持續改善。 我發現長期來看股價作爲業務表現的一種替代方法非常有趣。 但要真正獲得洞察力,我們還需要考慮其他信息。 關鍵是:我們已經發現angiodynamics有2個預警信號,你應該注意。
But note: AngioDynamics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:AngioDynamics可能不是最佳的股票購買選擇。 因此,瞥一眼這份有着過去盈利增長(以及未來增長預測)的有趣公司免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。